Clinical Evidence

Delve into clinical research studies and more

Clinical research lies at the heart of who we are. Vantive uses scientific evidence systematically, and transparently, to inform the development of new state-of-the-art solutions for patients around the world. Here you can find various studies, white papers and articles concerning important topics across the wide range of therapy areas served by Vantive.

HDx therapy enabled by the Theranova Dialyzer
How different is the clearance of large middle molecules and inflammatory markers from expanded hemodialysis therapy compared to online hemodiafiltration?
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Hypoalbuminemia: a price worth paying for improved dialytic removal of middle-molecular-weight uremic toxins?
Visit resource site
PD
Icodextrin Improves the Fluid Status of Peritoneal Dialysis Patients: Results of a Double-Blind Randomized Controlled Trial - Davies SJ, et al.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Immunomodulation Driven by Theranova Filter during a Single HD Session.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Impact of a medium cut-off dialyzer on skin autofluorescence in haemodialysis patients
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Impact of acetate-or citrate-acidified bicarbonate dialysate on ex vivo aorta wall calcification - Villa-Bellosta R. et al. Sci Rep 2019
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Impact of Expanded Hemodialysis Using Medium Cut-off Dialyzer on Quality of Life: Application of DynamicPatient-Reported Outcome Measurement Tool
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Impact of Medium Cut-Off Dialyzers on Patient-Reported Outcomes: COREXH Registry.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Impact of medium cut-off membranes on S100A12 and soluable receptor for advanced glycation end products
Visit resource site
PD
Impact of Peritoneal Dialysis (PD) Remote Monitoring on PD Services - Hendra H et al.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Impact of Single Hemodialysis Treatment on immune Cell Subpopulations
Visit resource site
PD
Implementation of an automated peritoneal dialysis program with remote monitoring in a network of renal clinics in Columbia - Mauricio S, et al.
Download PDF

Important Safety Information

INTENDED USE

The Theranova Dialyzer is indicated for patients with chronic kidney failure who are prescribed intermittent hemodialysis. It provides an expanded solute removal profile with increased removal of various middle molecules (up to 45 kDa) that may play a pathologic role in the uremic clinical syndrome. The Theranova Dialyzer is not intended for hemofiltration or hemodiafiltration therapy. The total extracorporeal blood volume for the Theranova Dialyzer and the set should represent less than 10% of the patient's blood volume.

For single use only.

 

Rx Only. For safe and proper use of the products mentioned herein, please refer to the appropriate Operator’s Manual or Instructions for Use.

 

Vantive, HDx and Theranova are trademarks of Vantive Health LLC or its affiliates.